Although ICG-001 has high biochemical specificity for the N-terminus of CBP, its mechanism of action is highly pleiotropic via the modulation of enhancers and super-enhancers in multiple cell types beyond tumor cells themselves, including mesenchymal, endothelial, and immune cell populations (40, 59, 61). This evidence concerns the gene CREBBP and neoplasm.